Aleix Prat

Sobre mi

Publicacions destacades

• Development and validation of the new HER2DX assay for predicting pathological response and survival outcome in early-stage HER2-positive breast cancer

  Autors:

  Prat, A; Brasó-Maristany, F; Sanfeliu, E; Schettini, F; Martínez, D;

  (...)

  Vivancos, A; Llombart-Cussac, A; Mira, A; Parker, JS; Perou, CM.

  Veure llistat complet d'autors

  Referència: Ebiomedicine 2022.

• Correlative Biomarker Analysis of Intrinsic Subtypes and Efficacy Across the MONALEESA Phase III Studies

  Autors:

  Prat, A; Chic, N; Martínez-Sáez, O; Brasó-Maristany, F; Paré, L;

  (...)

  Solovieff, N; Lteif, A; Babbar, N; Su, F; Taran, T.

  Veure llistat complet d'autors

  Referència: Journal Of Clinical Oncology 2021.

• A multivariable prognostic score to guide systemic therapy in early-stage HER2-positive breast cancer: a retrospective study with an external evaluation

  Autors:

  Prat, Aleix; Guarneri, Valentina; Pare, Laia; Griguolo, Gaia; Pascual, Tomos;

  (...)

  Piacentini, Federico; D'Amico, Roberto; Tagtiapco, Enrico; Parker, Joel S; Conte, Pierfranco.

  Veure llistat complet d'autors

  Referència: Lancet Oncology 2020.

• Immune-related adverse events of checkpoint inhibitors

  Autors:

  Ramos-Casals, M; Flores-Chávez, A; Brahmer, JR; Callahan, MK; Keegan, N;

  Khamashta, MA; Lambotte, O; Marlette, X; Prat, A; Suarez-Almazor, ME.

  Referència: Nature Reviews Disease Primers 2020.

• HER2-enriched subtype and pathological complete response in HER2-positive breast cancer: A systematic review and meta-analysis

  Autors:

  Schettini, F; De Placido, S; Pascual, T; Bráso-Maristany, F; Galván, P;

  (...)

  Schiff, R; Veeraraghavan, J; Rimawi, MF; Osborne, CK; Carey, LA.

  Veure llistat complet d'autors

  Referència: Cancer Treatment Reviews 2020.

• Phenotypic changes of HER2-positive breast cancer during and after dual HER2 blockade

  Autors:

  Brasó-Maristany, F; Griguolo, G; Pascual, T; Vidal, M; Adamo, B;

  (...)

  Manso, L; Alarcón, J; Martínez, E; Gregorio, S; Gomis, RR.

  Veure llistat complet d'autors

  Referència: Nature Communications 2020.

• Ribociclib plus letrozole versus chemotherapy for postmenopausal women with hormone receptor-positive, HER2-negative, luminal B breast cancer (CORALLEEN): an open-label, multicentre, randomised, phase 2 trial

  Autors:

  Prat, A; Saura, C; Pascual, T; Muñoz, M; Paré, L;

  (...)

  Hoyos, S; Rojas, B; Virizuela, JA; Ortega, V; López, R.

  Veure llistat complet d'autors

  Referència: Lancet Oncology 2020.

• HER2-Enriched Subtype and ERBB2 Expression in HER2-Positive Breast Cancer Treated with Dual HER2 Blockade

  Autors:

  Prat, A; Pascual, T; Paré, L; Adamo, B; Brasó-Maristany, F;

  (...)

  Parker, JS; Dieci, MV; Griguolo, G; Conte, P; Guarneri, V.

  Veure llistat complet d'autors

  Referència: Journal Of The National Cancer Institute 2020.

• A combinatorial biomarker predicts pathologic complete response to neoadjuvant lapatinib and trastuzumab without chemotherapy in patients with HER2+ breast cancer

  Autors:

  Veeraraghavan, J; De Angelis, C; Mao, R; Wang, T; Herrera, S;

  (...)

  Reis-Filho, J S; Gutierrez, C; Osborne, C K; Rimawi, M F; Schiff, R.

  Veure llistat complet d'autors

  Referència: Annals Of Oncology 2019.

• Association between PD1 mRNA and response to anti-PD1 monotherapy across multiple cancer-types.

  Autors:

  Pare, L; Pascual, T; Segui, E; Teixido, C; Gonzalez-Cao, M;

  (...)

  Juan, M; Llovet, J M; Reguart, N; Arance, A; Prat, A.

  Veure llistat complet d'autors

  Referència: Annals Of Oncology 2018.

Projectes destacats

• RESCUER: Resistance Under Combinatorial Treatment in ER+ and ER- Breast Cancer.

  Investigador/a principal: Aleix Prat Aparicio, Antoni Hurtado Rodríguez

  Finançador: European Commission

  Codi: H2020-SC1-BHC-02-2019 / 847912-2

  Durada: 01/01/2020 - 31/12/2024

• Adoptive cell therapy using CD3+/PD1+ tumor infiltrating lymphocytes in patients with advanced breast cancer

  Investigador/a principal: Aleix Prat Aparicio

  Finançador: Asociación Española Contra el Cáncer

  Codi: GCAEC19010PRAT

  Durada: 01/12/2019 - 30/11/2024

• Caracterización de los linfocitos T CD8+/PD1+ en cáncer de mama avanzado receptor hormonal-positivo con un fenotipo agresivo HER2-enriched.

  Investigador/a principal: Aleix Prat Aparicio

  Finançador: Merck Farma y Química, S.L

  Codi: 19-IO-011

  Durada: 01/07/2019 - 30/06/2021

• Targeting the HER2-enriched phenotype in hormone receptor-positive breast cancer  

  Investigador/a principal: Aleix Prat Aparicio

  Finançador: Instituto de Salud Carlos III

  Codi: INT_BCN_Catalyst_18

  Durada: 01/03/2019 - 28/02/2023

• Prospective exploratory study for determination of circulating tumor DNA (ctDNA) in blood samples from patients treated for breast cancer in follow-up and without evidence of relapse (B-CRONOS).

  Investigador/a principal: Aleix Prat Aparicio

  Finançador: Fundación Quirón Salud

  Codi: FQuironSalud_Mama18

  Durada: 11/02/2019 - 10/02/2022